Daily Cardiology Research Analysis
Three high-impact cardiology studies refine risk stratification and management. New echocardiography-based left ventricular mass index thresholds better predict 5-year mortality. High-sensitivity C-reactive protein robustly predicts cardiovascular events in a large primary prevention cohort. Post-PCI fractional flow reserve shows durable prognostic value over 5 years, especially for nonstented segments.
Summary
Three high-impact cardiology studies refine risk stratification and management. New echocardiography-based left ventricular mass index thresholds better predict 5-year mortality. High-sensitivity C-reactive protein robustly predicts cardiovascular events in a large primary prevention cohort. Post-PCI fractional flow reserve shows durable prognostic value over 5 years, especially for nonstented segments.
Research Themes
- Refining cardiovascular risk thresholds and biomarkers
- Long-term prognostic value of coronary physiology after PCI
- Integrating inflammation into primary prevention risk models
Selected Articles
1. Increasing Left Ventricular Mass and Death in Men and Women Investigated With Echocardiography.
In >300,000 echocardiograms with external validation, the mortality risk threshold for left ventricular mass index was lower than traditional LVH cutoffs in both sexes. Sex-stratified LVMi categories based on incremental 5-year mortality improved risk discrimination versus current criteria, identifying high-risk individuals even without guideline-defined LVH.
Impact: Redefining LVMi thresholds with external validation could reshape LVH classification and risk stratification, influencing preventive therapies and follow-up intensity.
Clinical Implications: Consider adopting lower, sex-specific LVMi thresholds to identify patients at elevated mortality risk despite absence of guideline-defined LVH, prompting earlier risk factor optimization and surveillance.
Key Findings
- In 155,668 men and 147,880 women, the statistical LVMi threshold for increased mortality was lower than traditional LVH criteria.
- Sex-specific LVMi categories based on incremental 5-year mortality improved discrimination versus current definitions.
- External validation in a US Medicare-linked cohort confirmed the predictive performance.
- A high proportion of individuals had elevated mortality risk despite no LVH by traditional criteria.
Methodological Strengths
- Very large national echocardiography dataset with sex-stratified analysis
- External validation in an independent US Medicare-linked cohort
Limitations
- Observational design susceptible to residual confounding
- Potential measurement variability across centers and devices
Future Directions: Prospective studies and guideline committees should evaluate adoption of these thresholds and assess whether early interventions guided by lower LVMi reduce events.
BACKGROUND: Left ventricular hypertrophy (LVH) categories are based on left ventricular mass index (LVMi). This study aimed to generate and externally validate sex-stratified LVMi cutoffs according to incremental mortality risk. METHODS: LVH information was determined on 155 668 men (aged 61.3±17.3 years) and 147 880 women (61.8±18.3 years) from the National Echocardiography Database of Australia. Sex-specific mild to severe thresholds of the increasing 5-year mortality rate based on LVMi increme
2. C-reactive protein and cardiovascular risk in the general population.
In 448,653 UK Biobank participants free of ASCVD, higher hsCRP levels were independently associated with increased MACE, cardiovascular death, and all-cause death. hsCRP improved discrimination beyond conventional risk factors and yielded a 14.1% net reclassification improvement when integrated into SCORE2.
Impact: This large-scale analysis supports routine hsCRP assessment for primary prevention risk stratification and highlights residual inflammatory risk as a modifiable therapeutic target.
Clinical Implications: Consider measuring hsCRP to refine primary prevention risk estimates and guide anti-inflammatory or intensified preventive strategies in individuals with elevated levels.
Key Findings
- Among 448,653 participants without ASCVD, hsCRP >3 mg/L was associated with 34% higher MACE risk and 61% higher CV death compared with <1 mg/L.
- hsCRP ≥2 mg/L vs <2 mg/L was linked to 22% higher MACE and 37% higher CV death.
- hsCRP showed long-term stability (repeat measurement at 4.4 years) and ranked above conventional risk factors in predictive performance.
- Integration of hsCRP improved SCORE2 risk prediction with a 14.1% total net reclassification improvement.
Methodological Strengths
- Very large population-based cohort with robust adjustment
- Demonstrated reclassification improvement over established risk scores
Limitations
- Observational design limits causal inference
- Potential selection bias inherent to volunteer biobank cohorts
Future Directions: Trial-based evaluation of hsCRP-guided prevention strategies, and integration with multi-omic inflammatory profiling to personalize residual risk reduction.
BACKGROUND AND AIMS: High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation and predicts cardiovascular (CV) risk in individuals without known atherosclerotic CV disease (ASCVD). More information about its clinical relevance will help evaluate the general utility of hsCRP as a routine clinical biomarker to identify patients at residual risk. METHODS: In this population-based study, hsCRP was measured in 448 653 UK Biobank participants without known ASCVD. The association of hsCRP w
3. Long-Term and Temporal Relationships Between Post-Stent Fractional Flow Reserve and Clinical Outcomes.
In 2,128 patients with 5-year follow-up, low post-PCI FFR was associated with increased target vessel failure, most pronounced within 3 years. Notably, revascularization in nonstented segments remained elevated in the low FFR group both within and beyond 3 years, underscoring the prognostic relevance of residual diffuse disease.
Impact: Clarifies the temporal prognostic window of post-PCI FFR and highlights persistent risk in nonstented segments, informing procedural optimization and long-term surveillance.
Clinical Implications: Aim for optimal post-PCI physiology and consider closer follow-up for low post-PCI FFR, with attention to nonstented segments where revascularization risk persists beyond 3 years.
Key Findings
- Low post-PCI FFR was associated with higher 5-year target vessel failure (adjusted HR 1.95 vs high FFR).
- The excess TVF risk in low FFR was most prominent within 3 years (aHR 2.00) and attenuated thereafter.
- Only target vessel revascularization in nonstented segments remained significantly elevated both ≤3 years (aHR 2.78) and >3 years (aHR 6.73) in low FFR.
- Findings emphasize residual diffuse disease beyond stented lesions as a driver of late events.
Methodological Strengths
- Large multicenter cohort with 5-year follow-up and adjusted analyses
- Granular lesion-level assessment distinguishing nonstented segments
Limitations
- Observational design without randomization to physiology targets
- Potential variability in post-PCI FFR measurement protocols
Future Directions: Prospective trials targeting post-PCI FFR optimization and strategies addressing diffuse nonstented disease; integration with physiologic imaging or physiology-guided follow-up.
BACKGROUND: Fractional flow reserve (FFR) following percutaneous coronary intervention (PCI) reflects the degree of flow limitation caused by residual disease after PCI. OBJECTIVES: The aim of this study was to evaluate the long-term and temporal prognostic impact of post-PCI FFR on clinical outcomes over a 5-year follow-up period. METHODS: A total of 2,128 patients who underwent angiographically successful drug-eluting stent implantation with post-PCI FFR measurement and completed 5 years of foll